Skip to main content
. 2021 Sep 24;26(19):5790. doi: 10.3390/molecules26195790

Figure 2.

Figure 2

Vilazodone significantly inhibits expression of established AIMs, while not affecting the prokinetic effects of L-DOPA. (A) Experimental design/timeline of study. (B–E) AIMs in 6-OHDA-lesioned rats treated with vehicle (10% cremophor in 0.9% saline) + L-DOPA (5 mg/kg, i.p.) (6/Veh/LD) for two weeks (B,C), and in 6-OHDA-lesioned rats treated with vehicle + L-DOPA (6/Veh/LD) in week 1 followed by vilazodone (10 mg/kg, i.p.) + L-DOPA (6/VIL/LD) in week 2 (D,E). The video analysis revealed that vilazodone co-administration in week 2 significantly attenuated the expression of AIMs compared to L-DOPA-only treatment in week 1, for axial, limb and orolingual AIMs (individual animals) (D) and for total AIM scores (mean ± SEM) across 180 min after L-DOPA administration (E). *** p < 0.001, 6/VIL/LD (week 2) vs. 6/Veh/LD (week 1). (F) Forelimb stepping scores after these drug treatments. Scores (mean ± SEM) from 4 weeks after the lesion (before the start of the treatment protocol, “baseline”) and 1 h after L-DOPA administration on the second day of treatment week 2 are shown. The forelimb stepping test revealed that vilazodone, while inhibiting L-DOPA-induced AIMs, did not negate the prokinetic effects of L-DOPA in stepping behavior (6/VIL/LD vs. 6/Veh/LD, p > 0.05). ### p < 0.001, vs. ipsilateral (INTACT) side; *** p < 0.001, vs. contralateral (LESION) baseline.